Stockscreener 앱 받기
5.12
8.02%
0.38
시간 외 거래:
5.01
-0.11
-2.15%
전일 마감가:
$4.74
열려 있는:
$4.88
하루 거래량:
717.93K
Relative Volume:
1.11
시가총액:
$68.96M
수익:
-
순이익/손실:
$-27.71M
주가수익비율:
-1.2015
EPS:
-4.2615
순현금흐름:
$-19.77M
1주 성능:
+4.70%
1개월 성능:
+12.04%
6개월 성능:
+34.03%
1년 성능:
+15.06%
1일 변동 폭
$4.65
$5.30
1주일 범위
$4.62
$5.30
52주 변동 폭
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
명칭
Cingulate Inc
전화
(913) 942-2300
주소
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
5.12 | 66.40M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2023-12-22 | 다운그레이드 | Laidlaw | Buy → Hold |
Cingulate Inc 주식(CING)의 최신 뉴스
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com Australia
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - TMX Newsfile
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - AJMC
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online
Biopharma bites: FDA rebuffs Cingulate's ADHD hopeful, plus Contraline's male contraceptive funding - FirstWord Pharma
FDA rejects Cingulate's application for ADHD medicine - The Business Journals
FDA Sends Complete Response Letter for Cingulate's CTx-1301 | PharmExec - PharmExec.com
FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns - HCPLive
Cingulate Gets FDA Request for Updates on ADHD Drug Application - Moomoo
Cingulate Inc - Reuters
Cingulate Inc. Q1 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 19%Earnings Preview - thelegaladvocate.com
Cingulate Receives FDA Complete Response Letter for CTx-1301 ADHD Drug; No Clinical Safety or Efficacy Concerns Identified 1 - Minichart
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues - Reuters
FDA Sends CRL to Cingulate for CTx-1301 - PharmExec.com
ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection - Fierce Pharma
Cingulate stock tumbles after FDA issues response letter - Investing.com
Cingulate receives FDA complete response letter for ADHD drug By Investing.com - Investing.com South Africa
Cingulate stock tumbles after FDA issues response letter By Investing.com - Investing.com Australia
Cingulate receives FDA complete response letter for ADHD drug - Investing.com
Cingulate Faces FDA Delay But Maintains ADHD Drug Plans - TipRanks
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - The Manila Times
Cingulate receives FDA complete response letter for CTx-1301; CMC requests, ~$30M cash - TradingView
FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301 - Stock Titan
US FDA declines to approve Cingulate's ADHD drug - Yahoo Finance
Reportable, Inc. - TMX Newsfile
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Cingulate Nears FDA Verdict on ADHD Drug Amid Manufacturing Hurdles - BriefGlance
Executive pay and equity plan on agenda at Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Awaits FDA Decision On ADHD Therapy CTx-1301 - RTTNews
CING Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D InvestmentEarnings Cycle Outlook - The League of Women Voters of Texas
CING Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerRevenue Growth Outlook - thelegaladvocate.com
Cingulate Inc. (CING) Plunges 17% as Selling Pressure IntensifiesEase of Movement - thelegaladvocate.com
Analysts Are Bullish on These Healthcare Stocks: Roche Holding AG (RHHVF), Cingulate Inc (CING) - The Globe and Mail
H.C. Wainwright Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Cingulate Inc. (CING) Surges 8.4% as Bullish Momentum BuildsImpulse Wave - thelegaladvocate.com
CING Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision - Investing.com UK
Cingulate Inc (CING) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cingulate Inc 주식 (CING) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Werth Peter J. | Director |
Feb 06 '26 |
Buy |
5.04 |
19,455 |
98,053 |
117,449 |
| Callahan Jennifer L. | SVP and CFO |
Feb 06 '26 |
Buy |
5.04 |
4,864 |
24,515 |
5,059 |
| Schaffer Shane J. | Chief Executive Officer |
Feb 06 '26 |
Buy |
5.04 |
6,809 |
34,317 |
10,175 |
| Brams Matthew | EVP and Chief Medical Officer |
Feb 06 '26 |
Buy |
5.04 |
1,946 |
9,808 |
4,656 |
2.60%
0.94%
자본화:
|
볼륨(24시간):